Asia Pacific Chronic Cough Market
市场介绍
慢性咳嗽的定义是持续时间长达6小时的持续性咳嗽-8周。它会扰乱睡眠、呕吐、头晕，甚至肋骨骨折，严重影响患者的生活。它是由感染、哮喘、胃食管反流病（GERD）等多种原因引起的。
市场概况和动态
亚太地区慢性咳嗽市场预计将从 2019 年的 11.3666 亿美元增长到 2027 年的 21.5525 亿美元。 2020年至2027年复合年增长率为8.4%。亚太地区慢性咳嗽市场的增长归因于慢性咳嗽发病率的上升以及治疗慢性咳嗽的产品开发的不断增长。然而，产品召回限制了该地区市场的增长。由于 COVID-19 的不断增长，亚太地区国家预计将面临巨大的挑战。受疫情影响，医疗保健行业受到严重影响。由于冠状病毒病例不断增加，许多与业务相关的活动（例如产品发布会和产品推广会议）被推迟，从而限制了市场的增长。
主要细分市场
根据药物类别，亚太地区慢性咳嗽市场分为抗组胺药、皮质类固醇、减充血剂、复方药物、抗生素、酸阻滞剂等药物类。 2019年，复方药物领域占据了更大的市场份额，预计在预测期内将以更快的速度增长。
主要来源和上市公司
在准备亚太慢性咳嗽市场报告时提到的一些主要一手和二手来源是世界卫生组织、卫生部健康和家庭福利部以及澳大利亚治疗产品管理局。Novartis AG、Teva Pharmaceutical Industries Ltd、GlaxoSmithKline plc.、Bayer AG、Mylan NV、Amneal Pharmaceuticals, Inc.、Cipla Inc.、Reckitt Benckiser Group plc.、Sun Pharmaceutical Industries Ltd、Aurobindo Pharma Ltd.
购买报告的理由
< span>
按药物类别
· 抗组胺药
· 皮质类固醇
· 减充血剂
· 复方药物
· 抗生素
· 酸阻滞剂
· 其他药物类别
按给药途径
· 口头
· 注射
· 鼻音
· 其他给药途径
按分销渠道
· 医院药房
· 网上药店
· 零售药店
按国家/地区
· ; 日本
· 中国
· 印度
· 韩国
· 澳大利亚
公司简介
Strategic insights for Asia Pacific Chronic Cough involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 1,136.66 Million |
| Market Size by 2027 | US$ 2,155.25 Million |
| Global CAGR (2020 - 2027) | 8.4% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By 药物类别
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia Pacific Chronic Cough refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Chronic Cough Market is valued at US$ 1,136.66 Million in 2019, it is projected to reach US$ 2,155.25 Million by 2027.
As per our report Asia Pacific Chronic Cough Market, the market size is valued at US$ 1,136.66 Million in 2019, projecting it to reach US$ 2,155.25 Million by 2027. This translates to a CAGR of approximately 8.4% during the forecast period.
The Asia Pacific Chronic Cough Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Chronic Cough Market report:
The Asia Pacific Chronic Cough Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Chronic Cough Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Chronic Cough Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Chronic Cough Market
